Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21085141 | 0.93 | SIGMAR1 (0.32) | ESR2CYP1A2CHRM2CHRM4CHRM5 | |
| SCHEMBL4069123 | 0.84 | — | — | |
| SCHEMBL79852 | 0.81 | — | — | |
| SCHEMBL1543625 | 0.81 | CYP1A2 (0.38) | ESR2CYP1A2CHRM2CHRM4CHRM5 | |
| SCHEMBL17090744 | 0.78 | — | — | |
| SCHEMBL21085070 | 0.78 | CYP1A2 (0.31) | CYP1A2 | |
| SCHEMBL79065 | 0.76 | — | — | |
| SCHEMBL78714 | 0.76 | — | — | |
| SCHEMBL18421585 | 0.76 | ESR2 (0.43) | ESR2CYP1A2 | |
| SCHEMBL18421980 | 0.76 | SIGMAR1 (0.37) | ESR2CYP1A2CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116783179-A | Compounds and methods for targeted degradation of androgen receptor proteins | 阿尔维纳斯运营股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| US-10759749-B2 | Therapeutic agent for diabetes | JCR PHARMACEUTICALS CO., LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| EP-3508474-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR Pharmaceuticals Co., Ltd. (JP) | 2019-07-10 | — | — | EP | disclosed |
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR PHARMACEUTICALS CO., LTD. (JP) | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | GPR119, IAPP, DPP4 | ESR2 4035/4885CYP1A2 4614/4885CHRM2 2831/4885 |
| US-10759749-B2 | Therapeutic agent for diabetes | GPR119, IAPP, DPP4 | ESR2 4360/4885CYP1A2 3926/4885CHRM2 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.